Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated a clinical-stage biopharmaceutical company focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811 which is in Phase 1 clinical trials in solid tumors including glioblastoma. The company is also developing PRT1419 a myeloid cell leukemia-1 inhibitor which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527 a cyclin-dependent kinase 4/6 inhibitor which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645 a cyclin-dependent kinase 4/6 inhibitor which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879 a SMARCA2 selective protein degrader which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington Delaware.